ECSP15045801A - Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida - Google Patents

Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida

Info

Publication number
ECSP15045801A
ECSP15045801A ECIEPI201545801A ECPI201545801A ECSP15045801A EC SP15045801 A ECSP15045801 A EC SP15045801A EC IEPI201545801 A ECIEPI201545801 A EC IEPI201545801A EC PI201545801 A ECPI201545801 A EC PI201545801A EC SP15045801 A ECSP15045801 A EC SP15045801A
Authority
EC
Ecuador
Prior art keywords
nicotinamide
pyrazole
hydroxy
phd inhibitors
phd
Prior art date
Application number
ECIEPI201545801A
Other languages
English (en)
Inventor
Jon Kuehler
Xiaolun Wang
Andre Kiryanov
Anthony Ivetac
Sean Murphy
Melinda Davis
Benjamin Jones
Jason Brown
Marion Lanier
Joanne Miura
Original Assignee
Eh Europe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eh Europe Gmbh filed Critical Eh Europe Gmbh
Publication of ECSP15045801A publication Critical patent/ECSP15045801A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención da a conocer compuestos de la fórmula (I), que son útiles como inhibidores de la PHD, composiciones farmacéuticas de los mismos, métodos para el tratamiento de condiciones asociadas al HIF, procesos para la elaboración de los compuestos e intermediarios de los mismos.
ECIEPI201545801A 2013-03-29 2015-10-29 Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida ECSP15045801A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361806806P 2013-03-29 2013-03-29
US201361916715P 2013-12-16 2013-12-16

Publications (1)

Publication Number Publication Date
ECSP15045801A true ECSP15045801A (es) 2017-02-24

Family

ID=50792544

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201545801A ECSP15045801A (es) 2013-03-29 2015-10-29 Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida

Country Status (40)

Country Link
US (5) US9040522B2 (es)
EP (2) EP2978752B1 (es)
JP (4) JP6282724B2 (es)
KR (1) KR102376354B1 (es)
CN (1) CN105492433B (es)
AP (1) AP2015008783A0 (es)
AU (1) AU2014241183B2 (es)
BR (1) BR112015020350B1 (es)
CA (1) CA2903875C (es)
CL (1) CL2015002473A1 (es)
CR (1) CR20150517A (es)
CY (1) CY1120029T1 (es)
DK (1) DK2978752T3 (es)
EA (1) EA031647B1 (es)
EC (1) ECSP15045801A (es)
ES (1) ES2660914T3 (es)
GE (1) GEP201706761B (es)
HR (1) HRP20180341T1 (es)
HU (1) HUE038220T2 (es)
IL (1) IL240803B (es)
JO (1) JO3722B1 (es)
LT (1) LT2978752T (es)
ME (1) ME03024B (es)
MX (1) MX370388B (es)
MY (1) MY184218A (es)
PE (1) PE20151860A1 (es)
PH (1) PH12015502248B1 (es)
PL (1) PL2978752T3 (es)
PT (1) PT2978752T (es)
RS (1) RS56974B1 (es)
SG (1) SG11201506749XA (es)
SI (1) SI2978752T1 (es)
SM (1) SMT201800112T1 (es)
TN (1) TN2015000397A1 (es)
TR (1) TR201802632T4 (es)
TW (1) TWI635084B (es)
UA (1) UA118965C2 (es)
UY (1) UY35513A (es)
WO (1) WO2014160810A1 (es)
ZA (1) ZA201506484B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370388B (es) 2013-03-29 2019-12-11 Takeda Pharmaceuticals Co Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhibidores de la enzima propil hidroxilasa (phd).
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
SG10201913595YA (en) 2016-09-30 2020-02-27 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MA49235B1 (fr) 2016-12-09 2021-02-26 Vertex Pharma Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
EP3634402B1 (en) 2017-06-08 2026-01-21 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN107163043A (zh) * 2017-06-16 2017-09-15 上海毕得医药科技有限公司 一种吡唑并[1,5‑a]吡啶‑3‑羧酸酯衍生物的合成方法
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
IL273831B2 (en) 2017-10-19 2024-10-01 Vertex Pharma Crystalline forms and compositions of cftr modulators
CN111757874B (zh) 2017-12-08 2024-03-08 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
WO2019195739A1 (en) * 2018-04-05 2019-10-10 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020156571A1 (zh) * 2019-02-02 2020-08-06 杭州华东医药集团新药研究院有限公司 一种哒嗪衍生物及其制备方法和医药用途
JP2023518543A (ja) * 2020-03-20 2023-05-02 アケビア セラピューティクス インコーポレイテッド Ｐｈｄ阻害剤化合物、組成物、及びそれらの使用
US20230227426A1 (en) * 2020-03-20 2023-07-20 Akebia Therapeutics, Inc. Phd inhibitor compounds, compositions, and use
AU2021240044A1 (en) * 2020-03-20 2022-11-17 Akebia Therapeutics, Inc. PHD inhibitor compounds, compositions, and use
TW202200134A (zh) 2020-04-20 2022-01-01 美商阿克比治療有限公司 治療病毒感染、器官損傷及相關症狀之方法
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物
JP7710897B2 (ja) * 2021-06-01 2025-07-22 三菱ガス化学ネクスト株式会社 １－アルキル－５－ヒドロキシピラゾールの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004022540A2 (en) * 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007020426A1 (en) 2005-08-19 2007-02-22 Astrazeneca Ab Pyrazolone derivatives for the treatment of tuberculosis
MX2009000286A (es) * 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
JP4388997B2 (ja) * 2006-09-05 2009-12-24 協和発酵キリン株式会社 イミダゾール誘導体
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
PT2439205E (pt) 2006-12-29 2015-07-16 Abbvie Deutschland Compostos de carboxamida e seus usos como inibidores de calpaína
DE102007044032A1 (de) 2007-09-14 2009-03-19 Bayer Healthcare Ag Substituierte heterocyclische Verbindungen und ihre Verwendung
CN102036981B (zh) * 2008-03-18 2015-04-08 默沙东公司 取代的4-羟基嘧啶-5-甲酰胺
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
MX2011007054A (es) * 2008-12-29 2011-11-29 Sanofi Sa Derivados de 2-il-pirazol-3(2h)-ona, su preparacion y su aplicacion en terapeutica como activadores de hif.
CA2748413A1 (fr) * 2008-12-29 2010-07-08 Sanofi Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
MX370388B (es) * 2013-03-29 2019-12-11 Takeda Pharmaceuticals Co Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhibidores de la enzima propil hidroxilasa (phd).

Also Published As

Publication number Publication date
PL2978752T3 (pl) 2018-06-29
IL240803B (en) 2019-02-28
BR112015020350A2 (pt) 2017-07-18
GEP201706761B (en) 2017-10-25
SI2978752T1 (en) 2018-04-30
JP6640978B2 (ja) 2020-02-05
TWI635084B (zh) 2018-09-11
US9345713B2 (en) 2016-05-24
MY184218A (en) 2021-03-26
JP2020073538A (ja) 2020-05-14
KR102376354B1 (ko) 2022-04-04
SG11201506749XA (en) 2015-09-29
US20160251337A1 (en) 2016-09-01
US20150224113A1 (en) 2015-08-13
PH12015502248A1 (en) 2016-02-01
ME03024B (me) 2018-10-20
BR112015020350B1 (pt) 2023-04-25
CN105492433B (zh) 2018-11-23
JP6282724B2 (ja) 2018-02-21
US10407409B2 (en) 2019-09-10
KR20150135794A (ko) 2015-12-03
US20140296200A1 (en) 2014-10-02
CN105492433A (zh) 2016-04-13
MX2015013687A (es) 2016-02-25
HK1217701A1 (en) 2017-01-20
TN2015000397A1 (en) 2017-01-03
UA118965C2 (uk) 2019-04-10
PH12015502248B1 (en) 2016-02-01
JP2018083838A (ja) 2018-05-31
JO3722B1 (ar) 2021-01-31
WO2014160810A1 (en) 2014-10-02
ZA201506484B (en) 2017-11-29
US9944626B2 (en) 2018-04-17
EA201591889A1 (ru) 2016-01-29
LT2978752T (lt) 2018-03-26
US20180186772A1 (en) 2018-07-05
CA2903875C (en) 2021-07-20
TW201446752A (zh) 2014-12-16
US9040522B2 (en) 2015-05-26
DK2978752T3 (en) 2018-03-12
AU2014241183B2 (en) 2018-08-09
TR201802632T4 (tr) 2018-03-21
EP3336084B1 (en) 2021-03-17
PE20151860A1 (es) 2015-12-16
RS56974B1 (sr) 2018-05-31
EA031647B1 (ru) 2019-02-28
EP2978752A1 (en) 2016-02-03
JP6874114B2 (ja) 2021-05-19
CY1120029T1 (el) 2018-12-12
HUE038220T2 (hu) 2018-10-29
EP3336084A1 (en) 2018-06-20
JP2019069997A (ja) 2019-05-09
HRP20180341T1 (hr) 2018-04-20
JP6462911B2 (ja) 2019-01-30
PT2978752T (pt) 2018-03-09
UY35513A (es) 2014-10-31
AU2014241183A1 (en) 2015-09-24
MX370388B (es) 2019-12-11
ES2660914T3 (es) 2018-03-26
CR20150517A (es) 2016-01-12
JP2016515582A (ja) 2016-05-30
IL240803A0 (en) 2015-10-29
CL2015002473A1 (es) 2016-08-26
AP2015008783A0 (en) 2015-10-31
US9708296B2 (en) 2017-07-18
NZ711522A (en) 2021-02-26
US20170275271A1 (en) 2017-09-28
EP2978752B1 (en) 2017-11-29
CA2903875A1 (en) 2014-10-02
SMT201800112T1 (it) 2018-05-02

Similar Documents

Publication Publication Date Title
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
MX2017003695A (es) Pirimidinonas como inhibidores del factor xia.
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
UY35971A (es) Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
MX375471B (es) Compuestos heteroaromaticos como inhibidores de btk.
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
MX340928B (es) Derivados de oxazolina e isoxazolina como moduladores de canales de calcio de liberación activa (crac).
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
DOP2016000211A (es) Pirazinas moduladoras de gpr6
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
GT201400169A (es) Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2
MX2017008373A (es) Compuestos, composiciones y metodos.
DOP2017000196A (es) Derivados de tetrahidropiranil benzamida
MX2017011388A (es) Proceso para la preparacion de derivados de fenilisoxazolina sustituida.